What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Vistagen Therapeutics Faces Class Action Lawsuit Following 80% Stock Plunge

Vistagen Therapeutics (VTGN) is facing a class action lawsuit after its stock price plummeted by more than 80% following the disclosure of clinical trial results. The legal action, filed by Levi & Korsinsky, LLP, aims to recover damages for investors who purchased the company's securities between April 1, 2024, and December 16, 2025. The massive sell-off was triggered by data from clinical trials, which raised significant concerns regarding the company's clinical pipeline and future prospects. Allegations in the lawsuit suggest potential violations of securities laws that may have adversely impacted shareholder value during the specified period. A deadline of March 16, 2026, has been established for investors to move the court to serve as lead plaintiff in the case. This litigation adds significant pressure to the biotech firm as it navigates the fallout from its clinical setbacks and intense market volatility.

Vistagen Therapeutics Faces Class Action Lawsuit Following 80% Stock Plunge

Instruments